Hearing loss due to concurrent daily low-dose cisplatin chemoradiation for locally advanced head and neck cancer

Zuur, Charlotte L.; Simis, Yvonne J.; Verkaik, Roxanna S.; Schornagel, J. H.; Balm, Alfons J. M.; Dreschler, Wouter A.; Rasch, Coen R. N.

doi:10.1016/j.radonc.2008.06.003

Cited by 44 publications

(51 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most distinguished toxicities associated with this drug include its neurotoxicity, nephrotoxicity and ototoxicity, which are related to high peak plasma concentration levels. 116 As a matter of fact, these drugs might be rationally efficient in the adjuvant setting, but their modest toxicity profiles need to be improved to ensure their safety, efficacy and tolerability in combination therapies. For this purpose, various antitumor drug-loaded nanocarriers were used for their chemotherapeutic action as novel techniques for the targeted drug delivery through the locoregional lymphatics, leading to improved drug delivery and targeting tumorous cells with the lowest systemic toxicity while retaining therapeutic systemic levels.…”

Section: Breast Tumormentioning

confidence: 99%

Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors

Din

Aman

Ullah³

et al. 2017

IJN

1,166

481

View full text Add to dashboard Cite

Nanotechnology has recently gained increased attention for its capability to effectively diagnose and treat various tumors. Nanocarriers have been used to circumvent the problems associated with conventional antitumor drug delivery systems, including their nonspecificity, severe side effects, burst release and damaging the normal cells. Nanocarriers improve the bioavailability and therapeutic efficiency of antitumor drugs, while providing preferential accumulation at the target site. A number of nanocarriers have been developed; however, only a few of them are clinically approved for the delivery of antitumor drugs for their intended actions at the targeted sites. The present review is divided into three main parts: first part presents introduction of various nanocarriers and their relevance in the delivery of anticancer drugs, second part encompasses targeting mechanisms and surface functionalization on nanocarriers and third part covers the description of selected tumors, including breast, lungs, colorectal and pancreatic tumors, and applications of relative nanocarriers in these tumors. This review increases the understanding of tumor treatment with the promising use of nanotechnology.

show abstract

Section: Breast Tumormentioning

confidence: 99%

Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors

Din

Aman

Ullah³

et al. 2017

IJN

1,166

481

View full text Add to dashboard Cite

show abstract

“…10,11 In fact, more than 80% of patients experience severe toxic effects with current regimens, and more than 75% of patients receiving cisplatin develop ototoxic effects, which are cumulative and usually irreversible. 12,13 …”

mentioning

confidence: 99%

Efficacy and Toxicity of Peritumoral Delivery of Nanoconjugated Cisplatin in an In Vivo Murine Model of Head and Neck Squamous Cell Carcinoma

Cohen

Rockefeller

Mukerji

et al. 2013

JAMA Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

Importance Treatment of locally advanced head and neck squamous cell carcinoma (HNSCC) uses a multi-disciplinary approach often limited by the toxicity and drug resistance of platinum agents. Objectives To test whether a nanocarrier-conjugated cisplatin boosting locoregional drug delivery improves tumor efficacy while decreasing systemic toxicity over systemic cisplatin in a murine model of locally advanced HNSCC. Design A randomized, controlled, in vivo study compared standard cisplatin with nanocarrier (hyaluronan [HA])–conjugated cisplatin (HA-cisplatin) each at 50% of the maximum tolerated doses in a murine model of locally advanced HNSCC (10 mice/arm, each injected with 1 × 106 MDA-1986 HNSCC cells, with phosphate-buffered saline and HA-only control arms). Mice were treated for 3 weeks and observed for 3 additional weeks. Setting Academic medical center. Participants Forty female Nu/Nu mice. Randomization and treatment arms were initiated once tumor volumes reached 30 mm3. Intervention Injection with MDA-1986 HNSCC cells followed by 3 weeks of treatment with cisplatin, HA-cisplatin, phosphate-buffered saline, or HA only. Main Outcomes and Measures Animal weights and tumor volumes were measured 3 times each week (modified RECIST [Response Evaluation Criteria in Solid Tumors]). At necropsy, animal kidneys were examined for nephrotoxic effects and cochleae were examined for ototoxic effects. Results The mice treated with HA-cisplatin showed superior tumor efficacy (1 with complete clinical response, 3 with partial response, 1 with stable disease, and 5 with progressive disease) compared with standard cisplatin (no animals with complete clinical response, 1 with partial response, 1 with stable disease, and 8 with progressive disease), which was statistically significant (P=.003). All control animals developed progressive disease. Weight loss and body score were surrogate measures of treatment toxicity. The HA-cisplatin group had the least weight loss (mean [SD], 10.8% [4.7%]) compared with the cisplatin group (13.6% [5.6%]; P=.25). Body score dropped to 2 or less in all cisplatin-treated mice but not in any HA-cisplatin–treated mice, which also lacked any histologic signs of nephrotoxic or ototoxic effects. Conclusions and Relevance Nanoconjugated HA-cisplatin significantly improves tumor efficacy with lower toxicity compared with standard cisplatin in locally advanced HNSCC in vivo, justifying additional translational studies.

show abstract

“…In this study, patients with variety of HNCs were included (Brain tumor, tongue, nasopharynx, parathyroid, face, jaw, tonsil, and orbital). Although in some studies the effect of radiation on threshold of hearing in patients with different HN tumors were evaluated (14, 22,23), in most of the studies, only patients with nasopharynx carcinoma were investigated (8,10,(24)(25)(26)(27)(28).…”

Section: Discussionmentioning

confidence: 99%

The Effect of Radiation Therapy on Hearing Loss in Patients with Head and Neck Cancer

et al. 2018

View full text Add to dashboard Cite

Background: Radiotherapy is one of the important components of head and neck cancer (HNC) treatment. This treatment method may cause a variety of side effects like oral problems, swelling, and hearing loss. Objectives: In this study, the effect of radiotherapy on hearing loss in patients with HNC was investigated. Methods: In this prospective cohort research, patients with head and neck cancer referring to the Shohadaye Tajrish Hospital during 2014 to 2015 were investigated. All of these patients were candidate for radiotherapy as the main treatment. The radiotherapy of patients was done by 3D-computer based treatment planning system, using their CT scan. In order to oncologic assessment, preand post-radiotherapy audiologic evaluations were done. The common toxicity criteria for the adverse events (CTCAE V4.02) of the National Cancer Institute (NCI) were used for ototoxicity. A bivariate latent variable model was used to assess the effect of received dose on the severity of hearing loss. Results: In this study, 66 patients with HNC were investigated. Among them, 46 patients (70%) were male. The mean (SD) age of patients was 45.33 (15.11). The incidence rate of hearing loss in these patients was about 18%. The result of statistical modeling showed a positive relationship between severity of HL and received dose of radiation (P < 0.001). Conclusions:In general, the findings of this study showed a direct relationship between radiation dose received by the ears and severity of hearing loss in patients with HNC. In this context, paying more attention to dose-prescription limits and standards for assessing radiation therapy associated ototoxicity are strictly recommended.

show abstract

Hearing loss due to concurrent daily low-dose cisplatin chemoradiation for locally advanced head and neck cancer

Cited by 44 publications

References 26 publications

Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors

Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors

Efficacy and Toxicity of Peritumoral Delivery of Nanoconjugated Cisplatin in an In Vivo Murine Model of Head and Neck Squamous Cell Carcinoma

The Effect of Radiation Therapy on Hearing Loss in Patients with Head and Neck Cancer

Contact Info

Product

Resources

About